IN THE CLAIMS

The following listing of claims will replace all prior versions of claims in the application:

1. (previously canceled)

2. (currently amended) A composition for [~~method of~~] treating at least one of virus-induced and inflammatory diseases [~~of skin and membranes~~] in [~~humans or~~] animals, said composition comprising:

[~~topical application of a composition comprising~~]

at least one of [~~one or more of the monounsaturated alcohols~~] octadecenol, eicosenol, docosenol, [~~and~~] tetracosenol and hexacosenol [~~mixed with polar hydrophilic salts in a total concentration~~] in a concentration of from 0.1 to 25 percent by weight [~~in~~] of an admixed [~~a~~] physiologically active carrier [~~to the inflamed skin or membrane of the patient to be treated, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone~~];

at least one salt of a fatty acid according to the formula R^1-COO^-M^+, wherein R^1 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_x$, x is at least one of 6, 8, 10, and 12, and M^+ is a monovalent alkali metal ion; and

at least one mixed ester according to the formula R^2-COO-R^3, wherein R^2 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_y$, y is at least one of 6, 8, 10 and 12, and R^3 is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;

wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.

3. (currently canceled)

4. (previously canceled)

5. (currently amended) [~~The method of claim 2 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.~~] The composition of claim 2,

comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

6. (currently cancelled)

7. (previously cancelled)

8. - **9**. (currently cancelled)

10. (previously cancelled)

11. – **12**. (currently cancelled)

13. (previously cancelled)

14. (currently amended) A [~~method of~~] composition for intravenous treatment of [~~treating humans or other mammals for~~] viral infections in animals, said composition comprising:

[~~intravenous introduction into the human or other mammal to be treated with~~] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound [~~composition consisting of~~] comprising [~~of one or more~~] at least one C_{18} to C_{24} monounsaturated alcohol[~~s mixed with polar hydrophilic salts in a total concentration~~] in a physiologically active carrier[~~, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone~~];

at least one salt of a fatty acid according to the formula R^1-COO^-M^+, wherein R^1 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_x$, x is at least one of 6, 8, 10, and 12, and M^+ is a monovalent alkali metal ion; and

at least one mixed ester according to the formula R^2-COO-R^3, wherein R^2 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_y$, y is at least one of 6, 8, 10 and 12, and R^3 is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;

wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.

15. (currently cancelled)

16. (previously cancelled)

17. (currently amended) [~~The method of claim 14 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.~~] The composition of claim **14**, comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

18. (currently cancelled)

19. (previously cancelled)

20. (currently amended) A composition for intramuscular treatment of [~~method of treating humans or other mammals for~~] viral infections in animals, said composition comprising:

[~~intramuscular introduction into the human or other mammal to be treated with~~] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound [~~composition consisting of~~] comprising [~~of one or more~~] at least one C_{18} to C_{24} monounsaturated alcohol[~~s mixed with polar hydrophilic salts in a total concentration~~] in a physiologically active carrier[~~, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone~~];

at least one salt of a fatty acid according to the formula R^1-COO^-M^+, wherein R^1 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_x$, x is at least one of 6, 8, 10, and 12, and M^+ is a monovalent alkali metal ion; and

at least one mixed ester according to the formula R^2-COO-R^3, wherein R^2 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_y$, y is at least one of 6, 8, 10 and 12, and R^3 is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;

wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.

21. (currently cancelled)

22. (previously cancelled)

23. (currently amended) [~~The method of claim 20 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.~~] The composition of claim **20**,

comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

24. (currently cancelled)

25. (previously cancelled)

26. (currently amended) A [~~method of~~] composition for trans-mucosal treatment of [~~treating humans or other mammals for~~] viral infections in animals, said composition comprising:

[~~trans-mucus membranal introduction into the human or other mammal to be treated with~~] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound [~~composition consisting of~~] comprising [~~of one or more~~] at least one C_{18} to C_{24} monounsaturated alcohol[~~s mixed with polar hydrophilic salts in a total concentration~~] in a physiologically active carrier[~~, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone~~];

at least one salt of a fatty acid according to the formula R^1-COO^-M^+, wherein R^1 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_x$, x is at least one of 6, 8, 10, and 12, and M^+ is a monovalent alkali metal ion; and

at least one mixed ester according to the formula R^2-COO-R^3, wherein R^2 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_y$, y is at least one of 6, 8, 10 and 12, and R^3 is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;

wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.

27. (currently cancelled)

28. (previously cancelled)

29. (currently amended) [~~The method of claim 26 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.~~] The composition of claim **26**, comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

30. (currently cancelled)

31. (previously cancelled)

32. (currently amended) A [~~method of~~] composition for transdermal treatment of [~~treating humans or other mammals for~~] viral infections in animals, said composition comprising:

[~~transdermal penetration into the human or other mammal to be treated with~~] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound [~~composition consisting of~~] comprising [~~of one or more~~] at least one C_{18} to C_{24} monounsaturated alcohol[~~s mixed with polar hydrophilic salts in a total concentration~~] in a physiologically active carrier[~~, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone~~];

at least one salt of a fatty acid according to the formula R^1-COO^-M^+, wherein R^1 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_x$, x is at least one of 6, 8, 10, and 12, and M^+ is a monovalent alkali metal ion; and

at least one mixed ester according to the formula R^2-COO-R^3, wherein R^2 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_y$, y is at least one of 6, 8, 10 and 12, and R^3 is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;

wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.

33. (currently cancelled)

34. (previously cancelled)

35. (currently amended) [~~The method of claim 32 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.~~] The composition of claim **32**, comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

36. (currently cancelled)

37. – **85**. (previously cancelled)

86. (currently amended) A [~~method of~~] composition for trans-membranal treatment of [~~treating humans and mammals for~~] viral infections in animals, said composition comprising:

an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound comprising [~~introducing a composition consisting essentially of one or more~~] at least one monounsaturated alcohol[s] having [~~from~~] between 18 [~~to~~] and 24 carbons [~~through a membrane into the circulatory system of a human or mammal to be treated with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight comprising inserting such alcohol composition mixed with polar hydrophilic salts in a total concentration~~] in at least one of a physiologically acceptable liquid, cream, gel[~~, or~~] and suppository carrier into at least one of [~~the~~] an anus [~~or~~] and vagina of the [~~human or mammal~~] animal to be treated[~~, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone~~];

at least one salt of a fatty acid according to the formula R^1-COO^-M^+, wherein R^1 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_x$, x is at least one of 6, 8, 10, and 12, and M^+ is a monovalent alkali metal ion; and

at least one mixed ester according to the formula R^2-COO-R^3, wherein R^2 comprises $CH_3(CH_2)_7CH=CHCH_2(CH_2)_y$, y is at least one of 6, 8, 10 and 12, and R^3 is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;

wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.

87. (currently cancelled)

88. (previously cancelled)

89. (currently amended) [~~The method of claim 86 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.~~] The composition of claim **86**,

comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

90. (currently cancelled)